What is Arctic Vision?
Arctic Vision is a prominent player in the ophthalmic biotechnology sector, headquartered in China. The company is dedicated to the advancement of novel therapeutic solutions for a spectrum of ophthalmic diseases. Its product pipeline encompasses stages from pre-clinical development through to commercialization, with a strategic focus on addressing critical unmet medical needs within China, across Asia, and on a global scale. The company's mission is to enhance the quality of life for a broad patient demographic suffering from eye conditions. Arctic Vision is guided by a leadership team possessing extensive expertise in the ophthalmic industry and is backed by prominent investors in the life sciences arena.
How much funding has Arctic Vision raised?
Arctic Vision has raised a total of $132M across 2 funding rounds:
Series A
$32M
Series B
$100M
Series A (2020): $32M with participation from Morningside Venture Capital
Series B (2021): $100M led by Octagon Capital, New World Development Group, Dr. Adrian Cheng, Pivotal bioVenture Partners China, Loyal Valley Capital, Nan Fung Life Sciences, Tencent, and The Morningside Group
Key Investors in Arctic Vision
Morningside Venture Capital
Morningside Venture Capital is a venture capital firm with a history of making private equity and venture capital investments, often focusing on companies with strong entrepreneurial leadership and deep industry knowledge.
Nan Fung Life Sciences
Nan Fung Life Sciences is an investment arm focused on the life sciences sector, likely supporting companies with innovative technologies and therapeutic potential.
Tencent
Tencent is a major technology conglomerate providing internet and mobile services, known for its investments in various high-growth sectors, including healthcare and biotechnology.
What's next for Arctic Vision?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Arctic Vision. This capital infusion is expected to accelerate the development and commercialization of its innovative ophthalmic therapies, potentially targeting conditions such as glaucoma and uveitic macular edema. The company's trajectory suggests a strong focus on expanding its market presence, both domestically in China and internationally. Future endeavors will likely involve further clinical trials, regulatory submissions, and strategic partnerships to bring its promising treatments to patients worldwide. The backing from sophisticated investors indicates confidence in Arctic Vision's business model and its potential to capture significant market share in the rapidly evolving ophthalmic landscape.
See full Arctic Vision company page
